Long-term follow-up of lenalidomide + rituximab in iNHL
Nathan Fowler | ASH 2018 | Long-term updates on lenalidomide plus rituximab in FL
Nathan Fowler from MD Anderson Cancer Center discusses long-term updates on lenalidomide plus rituximab in FL.
Lenalidomide, rituximab, cyclophosphamide, and dexamethasone combination is tolerable and effective in previously untreated iNHL
The phase II trial investigated the feasibility and response to lenalidomide, rituximab, cyclophosphamide, and...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month